Your browser doesn't support javascript.
COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors.
Guo, Mengni; Liu, Jieying; Zhou, Shuntai; Yu, James; Ahmed, Zohaib; Ahmad, Sarfraz; Manoucheri, Manoucher; Socinski, Mark A; Mekhail, Tarek; Hsu, Vincent.
  • Guo M; Department of Internal Medicine, AdventHealth Orlando, Orlando, FL USA.
  • Liu J; Department of Internal Medicine, AdventHealth Orlando, Orlando, FL USA.
  • Zhou S; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC USA.
  • Yu J; Department of Internal Medicine, AdventHealth Orlando, Orlando, FL USA.
  • Ahmed Z; Department of Internal Medicine, AdventHealth Orlando, Orlando, FL USA.
  • Ahmad S; Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL USA.
  • Manoucheri M; Department of Internal Medicine, AdventHealth Orlando, Orlando, FL USA.
  • Socinski MA; Thoracic Cancer Program, AdventHealth Cancer Institute, Orlando, FL USA.
  • Mekhail T; Thoracic Cancer Program, AdventHealth Cancer Institute, Orlando, FL USA.
  • Hsu V; Department of Infectious Disease, AdventHealth Orlando, Orlando, FL USA.
SN Compr Clin Med ; 4(1): 193, 2022.
Article in English | MEDLINE | ID: covidwho-2007346
ABSTRACT
Cancer patients are a vulnerable population in the current coronavirus disease 2019 (COVID-19) outbreak. The impact of immune checkpoint inhibitors (ICIs) on the outcomes of COVID-19 infection in cancer patients remains largely unclear. We retrospectively investigated all solid cancer patients who received at least one cycle of ICIs at a single institution between August 2020 and August 2021. All stage IV solid cancer patients who were on or ceased ICI treatment when diagnosed with COVID-19 were eligible. All COVID-19 infections were confirmed by RT-PCR. Risk factors for hospitalization, severe symptoms, and death were analyzed. A total of 56 patients were included in our study. Twenty (35.7%) patients require hospitalization, 12 (21.4%) developed severe symptoms, and 10 (17.9%) died from COVID-19 infection. ICI treatment was interrupted in 37 patients (66.1%), 24 of whom (64.9%) had treatment resumed. Eight (80%) COVID-19-related death occurred in unvaccinated individuals. Reinfection occurred in seven patients (12.5%), and three of them died from their second COVID-19 infection. Factors associated with hospitalization were high Charlson comorbidity score (OR 1.56, 95% CI 1.10-2.23, p = 0.01) and lymphocyte ≤ 1500 mm3 (OR 10.05, 95% CI 2.03-49.85, p = 0.005). Age, chemoimmunotherapy, and ICI treatment duration were not associated with increased risk of hospitalization, severe symptoms, or COVID-19-related mortality. ICI therapy does not impose an increased risk for severe COVID-19 infection in stage IV cancer patients. Vaccination should be encouraged among this population. Clinicians should be cognizant of a potential worse outcome in COVID-19-reinfected patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal: SN Compr Clin Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal: SN Compr Clin Med Year: 2022 Document Type: Article